CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on the development of Omomyc, a peptide that inhibits the Myc oncogene, which is implicated in over 70% of cancers. The goal is to advance Omomyc towards clinical trials as a potential treatment for various cancers, demonstrating its effectiveness and safety.
Despite ever-increasing investments in the development of new treatments, many cancers remain incurable.
One reason is that most current therapies target redundant functions around which tumour cells can build resistance.
We focus instead on a unique and essential cellular function: the Myc oncogene, deregulated in more than 70% of human cancers.
Targeting Myc has long been considered unfeasible because of potentially catastrophic side effects.
Against this dogma, using a Myc inhibitor called Om…
FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
